News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
749,225 Results
Type
Article (53514)
Company Profile (365)
Press Release (695346)
Section
Business (217786)
Career Advice (2865)
Deals (37640)
Drug Delivery (113)
Drug Development (86511)
Employer Resources (181)
FDA (17173)
Job Trends (16083)
News (370069)
Policy (35994)
Tag
Academia (2884)
Alliances (53302)
Alzheimer's disease (1378)
Approvals (17112)
Artificial intelligence (184)
Bankruptcy (380)
Best Places to Work (12184)
Biotechnology (239)
Breast cancer (215)
Cancer (1605)
Cardiovascular disease (134)
Career advice (2402)
CAR-T (117)
Cell therapy (336)
Clinical research (69159)
Collaboration (600)
Compensation (311)
COVID-19 (2762)
C-suite (144)
Data (1499)
Diabetes (199)
Diagnostics (6557)
Earnings (88006)
Employer resources (158)
Events (118139)
Executive appointments (498)
FDA (17969)
Funding (529)
Gene therapy (239)
GLP-1 (714)
Government (4799)
Healthcare (20047)
Infectious disease (2863)
Inflammatory bowel disease (128)
Interviews (550)
IPO (16983)
Job creations (4334)
Job search strategy (1989)
Layoffs (479)
Legal (8922)
Lung cancer (241)
Manufacturing (233)
Medical device (13886)
Medtech (13891)
Mergers & acquisitions (20896)
Metabolic disorders (545)
Neuroscience (1773)
NextGen: Class of 2025 (7150)
Non-profit (4887)
Northern California (1892)
Obesity (311)
Opinion (236)
Patents (143)
People (61814)
Phase I (21420)
Phase II (30307)
Phase III (22743)
Pipeline (627)
Postmarket research (2967)
Preclinical (9169)
Radiopharmaceuticals (251)
Rare diseases (310)
Real estate (6565)
Regulatory (23955)
Research institute (2567)
Resumes & cover letters (454)
Southern California (1636)
Startups (3911)
United States (17111)
Vaccines (651)
Weight loss (235)
Date
Today (31)
Last 7 days (488)
Last 30 days (1920)
Last 365 days (36409)
2025 (1662)
2024 (36868)
2023 (41754)
2022 (52985)
2021 (57656)
2020 (56531)
2019 (49814)
2018 (37736)
2017 (34741)
2016 (34708)
2015 (40736)
2014 (34844)
2013 (30216)
2012 (32198)
2011 (32813)
2010 (31018)
Location
Africa (940)
Arizona (217)
Asia (43438)
Australia (7679)
California (4317)
Canada (1566)
China (373)
Colorado (195)
Connecticut (211)
Europe (95001)
Florida (606)
Georgia (149)
Illinois (451)
Indiana (252)
Maryland (714)
Massachusetts (3375)
Michigan (188)
Minnesota (329)
New Jersey (1210)
New York (1217)
North Carolina (852)
Northern California (1892)
Ohio (155)
Pennsylvania (1009)
South America (1326)
Southern California (1636)
Texas (627)
Utah (122)
Washington State (446)
749,225 Results for "rafael pharmaceuticals formerly known as cornerstone pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancer therapeutics, today announced that it is changing its name to Cornerstone Pharmaceuticals, Inc.
May 19, 2022
·
3 min read
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2025
January 9, 2025
·
2 min read
Business
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company’s Scientific Advisory Board.
July 6, 2022
·
3 min read
Drug Development
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 ® (devimistat) targeting carcinoma catabolism.
June 16, 2022
·
3 min read
Drug Development
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613® (devimistat) targeting carcinoma catabolism.
June 16, 2022
·
3 min read
Press Releases
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
January 7, 2025
·
8 min read
Press Releases
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
December 30, 2024
·
11 min read
Deals
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
Cyclo Therapeutics, Inc. today announced that it has closed the previously announced private placement with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for the purchase of 4,000,000 shares of common stock.
August 2, 2023
·
5 min read
Drug Development
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful completion of a Phase 1b clinical trial of CPI-613® (devimistat) in combination with gemcitabine and cisplatin for the treatment of advanced unresectable biliary tract cancer.
August 3, 2022
·
4 min read
1 of 74,923
Next